Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2016 Edition) on picking money-making stocks.This is an entirely free service. No payments are to be made.
|Live BSE Quotes||Oct 21, 2016 (Close)|
|Price (Rs)1,498.90||Open (Rs) 1,503.00||High (Rs) 1,518.00||Low (Rs) 1,493.25|
|% Change-0.19||Volume 37,390||Value (Rs) 56,164,378||52-Week H/L 2,096.30 / 1,294.05|
|Live NSE Quotes||Oct 21, 2016 (Close)|
|Price (Rs)1,500.10||Open (Rs) 1,507.50||High (Rs) 1,518.45||Low (Rs) 1,492.25|
|% Change-0.38||Volume 345,777||Value (Rs) 519,536,263||52-Week H/L 2,097.45 / 1,280.00|
|EPS (Rs)* 58.24||P/E Ratio (x) 25.73||Market Cap (Rs m) 676,212.25||P/BV (x) 6.16|
|*Trailing 12 months earnings, excluding extraordinary / exceptional items.||BSE Sensex | CNX Nifty|
|LUPIN LTD Stock Price Chart (Rs) - 1 Year|
Quote & Graph
S&P BSE SENSEX
Lupin has announced its 1QFY17results. Net sales have grown by 40% YoY and net profits have surged by 55.1% YoY. Here is our analysis of the results.
Lupin has announced its 4QFY16 results. Net sales have grown by 38.6% YoY, while net profits declined by 54.8% YoY. Here is our analysis of the results.
Lupin has announced its 2QFY16 results. Net sales have grown by 2% YoY, while net profits declined by 35.1% YoY. Here is our analysis of the results.
Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.
Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.More Views on News
A brief discussion on one BHK apartments going for Rs 1.8 crore in Mumbai and why it makes no sense.
How to sleep peacefully with dividend stocks.
Retail investors are flocking back to the Indian stock markets.
Apurva talks about his Secret Profit Signal and his first ever training session
PersonalFN explains why top performing mutual fund schemes may not always be the perfect fit for your investment portfolio.More